Pratteln, Switzerland – Santhera Pharmaceuticals (SIX: SANN) today reported positive topline results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating AGAMREE® (vamorolone) in patients with Duchenne muscular dystrophy (DMD). The long-term analysis included corticosteroid-naïve patients who began AGAMREE treatment between four and...
Latest News
Pratteln, Switzerland — Santhera Pharmaceuticals (SIX: SANN) announces that has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). In parallel to the MAA submission to the UK MHRA, Santhera is currently preparing...
Pratteln, Switzerland – The European Commission (EC) granted marketing authorization to vamorolone for the treatment of patients with Duchenne muscular dystrophy (DMD), who are 4 years of age and above, according to a press release from Santhera, the developers of the treatment. Vamorolone will be sold under the brand name...
Roswell, Ga, Dublin and Hamilton, Bermuda — Saol Therapeutics (“Saol”), a privately held, clinical-stage pharmaceutical company, announced the signing of an agreement with Medosome Biotec to provide Saol the rights to use their patented genotype test for all potential indications where SL-1009 might be used as a therapy. The test...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda — Saol Therapeutics, a privately held clinical-stage pharmaceutical company, today announced that the company has been granted a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss new data and a potential path forward for its New Drug Application (NDA)...
Specific gene profiles of bronchoalveolar lavage (BAL) cells are associated with phenotypic manifestations of sarcoidosis such as activity and disease severity, including immune, inflammatory, and profibrotic mediators as identified via genome-wide transcriptome analysis, according to results published in the European Respiratory Journal. Study results also suggest 4 possible sarcoidosis endotypes with specific...
CAMBRIDGE, Mass. — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly ARO-DM1), an investigational small interfering RNA (siRNA) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Cohorts...
CAMBRIDGE, Mass. — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in...
CAMBRIDGE, Mass. — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved dosing in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to evaluate the use of an enhanced immunosuppressive...
CAMBRIDGE, Mass. – Since Elevidys’ accelerated approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory children. New results, presented Friday, show mobility improvements in 8- to 9-year-old patients after one year of follow-up. Sarepta Therapeutics touted “statistically significant and clinically meaningful” functional improvements in...